Drugs / Al18F-NOTA-octreotide
Al18F-NOTA-octreotide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03883776 | Apr → Oct 2019 | neuroendocrine neoplasm | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04552847 | Oct 2020 → Feb 2022 | neuroendocrine neoplasm | Universitaire Ziekenhuizen KU Leuven | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Al18F-NOTA-octreotide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04552847 ↗ |
| Known as | [18F]AlF-NOTA-octreotide | “[18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the...” PMID 38837825 ↗ Jun 20241“the recently introduced [18F]AlF-NOTA-octreotide ([18F]AlF-OC).” PMID 32617641 ↗ Jul 2020 |
| Known as | [18F]AlF-OC | “[18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the...” PMID 38837825 ↗ Jun 20241“the recently introduced [18F]AlF-NOTA-octreotide ([18F]AlF-OC).” PMID 32617641 ↗ Jul 2020 |
| Known as | Al18F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide | “The aim of this study is to evaluate the potential of Al18F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide (Al18F-NOTA-octreotide) as a positron emission tomography (PET)...” NCT03883776 ↗ |
| Modality | Diagnostic / imaging agent | “as a positron emission tomography (PET) somatostatin receptor imaging agent” NCT03883776 ↗ |
| Route | Intravenous | “One intravenous injection of 4 MBq/kg” NCT03883776 ↗ |